Type 1 Diabetes and Depression: Role of Brain Glutamate

NCT ID: NCT05355285

Last Updated: 2022-05-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 68 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-01-31
• Study Completion Date: 2014-11-30

Brief Summary

The goal of this study is to examine the effect of chronic and acute hyperglycemia in type 1 diabetes mellitus (T1DM) on brain glutamate levels using magnetic resonance spectroscopy (MRS), and associations of brain glutamate with symptoms of depression.

Detailed Description

The research of this study is focused on elucidating the relationship between the perturbations in glucose metabolism associated with T1DM and the higher prevalence of major depressive episodes in this patient population. Converging evidence associating high brain levels of glutamate with T1DM and depression leads to the hypothesis that the link between diabetes-related glucose metabolic disorders and depression is excessive brain glutamate. The overarching aim of the study is to examine the effect of chronic and acute hyperglycemia in T1DM on brain glutamate levels. Four subject groups were studied and characterized: T1DM patients with and without concurrent depressive symptoms, and non-diabetic subjects with and without concurrent depressive symptoms. Two brain regions were examined : the anterior cingulate cortex (ACC), known to play an essential role in the regulation of emotions, and a control occipital cortex region. Regional brain glutamate concentrations were measured using high-field (3 Tesla) localized multidimensional magnetic resonance spectroscopy (MRS), regional indices of brain function were assessed using functional magnetic resonance imaging (fMRI), concurrent depression symptom severity and depression history were evaluated using psychiatric assessment, extensive medical evaluation of patients was performed including evaluation of glycemic control (HbA1c), evaluation of behavioral performance on emotional and cognitive tasks and evaluation of regional brain cortical thickness using high-resolution structural MRI. For all subjects, MRS brain glutamate was assessed during basal euglycemia and, for a subset of subjects per group, during an acute hyperglycemic clamp. To control for potential confounding effects of hyperinsulinemia, brain glutamate was also assessed during a euglycemic hyperinsulinemic clamp in a subset of healthy controls without diabetes or depressive symptoms.

Conditions

Type1diabetes; Depressive Symptoms; Major Depressive Disorder

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Baseline Euglycemia

Subjects with T1DM (Groups 1 and 2): 1) receive a low dose insulin infusion to reduce their plasma glucose to euglycemia; 2) receive a continuous infusion of insulin at the rate of 0.25 milli-Units/kg/min to maintain euglycemia during a Baseline MRI scanning period.

Subjects without diabetes (Groups 3 and 4) are scanned during a Baseline MRI scanning period (no intervention is needed to maintain euglycemia in these subjects).

Group Type: EXPERIMENTAL

Glucose Clamp

Intervention Type: PROCEDURE

Subjects receive variable rates of glucose or insulin infusions to adjust and maintain desired plasma glucose or insulin levels.

Hyperglycemic Clamp

Subjects with T1DM (Groups 1 and 2): 1) receive a primed variable glucose infusion to attain a target increase in glycemic level of +5.5 mmol/L; 2) receive a continuous infusion of insulin at the rate of 0.25 milli-Units/kg/min.

Subjects without diabetes (Groups 3 and 4): 1) receive a primed variable glucose infusion to attain a target increase in glycemic level of +5.5 mmol/L.

Group Type: EXPERIMENTAL

Glucose Clamp

Intervention Type: PROCEDURE

Subjects receive variable rates of glucose or insulin infusions to adjust and maintain desired plasma glucose or insulin levels.

Hyperinsulinemic Euglycemic Clamp

Subjects without diabetes or depression (Group 3) have a second study visit at least 15 days after the Hyperglycemic Clamp visit. They receive a variable insulin infusion to match individual insulin levels to the levels attained during the Hyperglycemic Clamp and they receive a variable glucose infusion to maintain euglycemia.

Group Type: EXPERIMENTAL

Glucose Clamp

Intervention Type: PROCEDURE

Subjects receive variable rates of glucose or insulin infusions to adjust and maintain desired plasma glucose or insulin levels.

Interventions

Glucose Clamp

Subjects receive variable rates of glucose or insulin infusions to adjust and maintain desired plasma glucose or insulin levels.

Intervention Type: PROCEDURE

Other Intervention Names

Hyperglycemic, Euglycemic, or Hyperinsulinemic Euglycemic Clamp

Eligibility Criteria

Inclusion Criteria

• 10-25 years duration of T1DM.
• Relatively low levels of complications from diabetes.

• No history of T1DM or Major Depressive Disorder.
• Normal fasting blood glucose, HbA1c and hematocrit levels.

• History of at least one episode of major depression.
• A 17-item HAM-D (HAMD-17) score ≥ 10 and ≤ 27

Exclusion Criteria

• Type 2 diabetes and/or gestational diabetes.
• Other major clinical conditions such as cancer, symptomatic coronary artery disease, (e.g., prior myocardial infarction), stroke, proliferative diabetic retinopathy requiring a laser treatment, clinically significant diabetic nephropathy as evidenced by urinary albumin levels > 300 mg/day and/or serum creatinine > 1.5 mg/dl for men and > 1.4 mg/dl for women, painful or symptomatic neuropathy, and/or diagnosed gastroparesis.
• Current or past history of attention deficit hyperactivity disorder, bipolar disorder, obsessive compulsive disorder, panic disorder, substance dependence or schizophrenia.
• Ethanol dependence and/or nicotine dependence according to Diagnostic and Statistical Manual-IV criteria and heavy smokers according to the Epidemiology of Diabetes Interventions and Complications scale 57.

Control Subjects:

• Known chronic medical illness such as rheumatoid arthritis or major cardiac, kidney or liver disease or anemia.
• Current or past history of attention deficit hyperactivity disorder, bipolar disorder, obsessive compulsive disorder, panic disorder, substance dependence or schizophrenia.
• Past history of a major depressive episode, as well as with current symptoms of depression as defined by a HAMD-17 score ≥ 10.

Subjects with depressive history and current depressive symptoms:

• Current or past history of attention deficit hyperactivity disorder, bipolar disorder, obsessive compulsive disorder, panic disorder, substance dependence or schizophrenia.
• Subjects under current treatment with antidepressant medication.
• Subjects with acute severe depression or acute suicidal ideation, who in the opinion of the psychiatrist are clinically inappropriate for participation in the study.
• Subjects who in the opinion of the psychiatrist are clinically inappropriate for a one-week delay in antidepressant medication treatment.
• HAMD-17 score > 27.

All Subjects:

Participants who have metal in their body, suffer from claustrophobia or panic disorder or women who are pregnant, or who are currently breast-feeding cannot participate in this research study.

• Cardiac pacemakers
• Metal clips on blood vessels (also called stents)
• Artificial heart valves
• Artificial arms, hands, legs, etc.
• Brain stimulator devices
• Implanted drug pumps
• Ear implants
• Eye implants or known metal fragments in eyes
• Exposure to shrapnel or metal filings (wounded in military combat, sheet metal workers, welders, and others)
• Other metallic surgical hardware in vital areas
• Certain tattoos with metallic ink (subjects are requested to inform the investigator if they have a tattoo)
• Certain transdermal (skin) patches such as NicoDerm (nicotine for tobacco dependence), Transderm Scop (scopolamine for motion sickness), or Ortho Evra (birth control).
• Claustrophobia

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Beth Israel Deaconess Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Nicolas Bolo

Director of Neuroimaging in Psychiatry

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Nicolas R Bolo, PhD

Role: PRINCIPAL_INVESTIGATOR

Beth Israel Deaconess Medical Center

References

Bolo NR, Jacobson AM, Musen G, Keshavan MS, Simonson DC. Acute Hyperglycemia Increases Brain Pregenual Anterior Cingulate Cortex Glutamate Concentrations in Type 1 Diabetes. Diabetes. 2020 Jul;69(7):1528-1539. doi: 10.2337/db19-0936. Epub 2020 Apr 15.

Reference Type: RESULT

PMID: 32295804 (View on PubMed)

Bolo NR, Jacobson AM, Musen G, Simonson DC. Hyperglycemia and hyperinsulinemia effects on anterior cingulate cortex myoinositol-relation to brain network functional connectivity in healthy adults. J Neurophysiol. 2022 May 1;127(5):1426-1437. doi: 10.1152/jn.00408.2021. Epub 2022 Apr 13.

Reference Type: RESULT

PMID: 35417272 (View on PubMed)

Other Identifiers

NIH R01-DK084202

Identifier Type: -

Identifier Source: org_study_id